人 SIGLEC6 抗体对
01AB00402
Sialic acid-binding Ig-like lectin 6 (SIGLEC6) is a transmembrane protein belonging to the SIGLEC family, primarily expressed in placenta, mast cells, and memory B-cells. It functions as an immunoreceptor that binds sialyl-TN glycans and leptin, playing a role in cell adhesion and migration, particularly in chronic lymphocytic leukemia (CLL). In CLL, SIGLEC6 is implicated in the interaction of B-cells with bone marrow stromal cells, affecting their migration and survival. Dysregulation of SIGLEC6 is associated with diseases such as indolent systemic mastocytosis and gestational trophoblastic disease, where it contributes to aberrant cellular proliferation and invasion. Its potential as a therapeutic target is underscored by studies indicating that SIGLEC6 engagement can enhance immune responses against cancer cells.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- SIGLEC6
- 基因别名
- CD33L; CD33L1; OBBP1
- 蛋白别名
- sialic acid binding Ig like lectin 6; SIGLEC6
- UniProt
- O43699
- 物种
- Human
产品详情
- 靶点名称
- SIGLEC6
- 蛋白名称
- sialic acid binding Ig like lectin 6
- 蛋白别名
- Sialic acid-binding Ig-like lectin 6; Siglec-6; CD33 antigen-like 1; CDw327; Obesity-binding protein 1; OB-BP1; CD antigen CD327
- 靶点基因名
- SIGLEC6
- 基因别名
- CD33L; CD33L1; OBBP1
- UniProt
- O43699
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Sialic acid-binding Ig-like lectin 6 (SIGLEC6) is a transmembrane protein belonging to the SIGLEC family, primarily expressed in placenta, mast cells, and memory B-cells. It functions as an immunoreceptor that binds sialyl-TN glycans and leptin, playing a role in cell adhesion and migration, particularly in chronic lymphocytic leukemia (CLL). In CLL, SIGLEC6 is implicated in the interaction of B-cells with bone marrow stromal cells, affecting their migration and survival. Dysregulation of SIGLEC6 is associated with diseases such as indolent systemic mastocytosis and gestational trophoblastic disease, where it contributes to aberrant cellular proliferation and invasion. Its potential as a therapeutic target is underscored by studies indicating that SIGLEC6 engagement can enhance immune responses against cancer cells.